Breaking Access Barriers to Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies—an ASTCT-NMDP ACCESS Initiative
Open Access
- 7 February 2026
- journal article
- review article
- Published by Elsevier in Transplantation and Cellular Therapy
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Barriers to Chimeric Antigen Receptor T-Cell TherapyJAMA Oncology, 2025
- Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and AgeJAMA Network Open, 2024
- Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United StatesCancer Medicine, 2021
- Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaCancer, 2020
- Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemiaCancer, 2020
- Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR reportCancer, 2017
- Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center studyCancer, 2014
- Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio‐geo‐demographic factors in the era of novel agentsAmerican Journal of Hematology, 2014
- Access to hematopoietic stem cell transplantationCancer, 2010
- Race, poverty, and survival in multiple myelomaCancer, 1984